following a full submission:
filgrastim (Nivestim) is accepted for use within NHS Scotland.
Indications under review: The reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes);
Reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia;
The mobilisation of peripheral blood progenitor cells (PBPC);
In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/l and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events;
The treatment of persistent neutropenia (ANC ≤ 1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.
Filgrastim (Nivestim) is a biosimilar product and has demonstrated equivalence in terms of efficacy and safety to a reference granulocyte colony stimulating factor, filgrastim (Neupogen).
The British National Formulary advises that it is good practice to prescribe biological medicinal products by brand name.
Download detailed advice102KB (PDF)
- Medicine name:
- filgrastim (Nivestim)
- SMC ID:
- for the reduction in the duration of neutropenia and the incidence of febrile neutropenia (FN) in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
- Pharmaceutical company
- Hospira UK Limited
- BNF chapter
- Nutrition and blood
- Submission type
- Date advice published
- 07 February 2011